Log in
Enquire now
‌

US Patent 9758506 Muscarinic agonists

Patent 9758506 was granted and assigned to Heptares Therapeutics on September, 2017 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
‌
Heptares Therapeutics
Current Assignee
‌
Heptares Therapeutics
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9758506
Date of Patent
September 12, 2017
Patent Application Number
15227325
Date Filed
August 3, 2016
Patent Citations Received
‌
US Patent 12024499 Muscarinic agonists
0
‌
US Patent 11773090 Pharmaceutical compounds
‌
US Patent 11834407 Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
0
‌
US Patent 11945801 Bicyclic aza compounds as muscarinic M
0
Patent Primary Examiner
‌
Sudhakar Katakam
Patent abstract

This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula (1a)

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9758506 Muscarinic agonists

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.